BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

July 2012

Comments

RED^1,2,3: NICE TA34: trastuzumab in combination with paclitaxel  is recommended for women with tumours with excessive human epidermal growth factor receptor 2 (HER2) at levels of 3+ who have not had chemotherapy for metastatic breast cancer and for whom anthracycline treatment is inappropriate. (March 2002)

RED^1,2,3:NICE TA107: Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).(August 2006)

RED1,2,3:NICE TA208: Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an option for the treatment of people with HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. (Nov 2010)  

DO NOT PRESCRIBE (DNP)6:NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) are not recommended for first-line treatment in post-menopausal women with metastatic hormone receptor positive breast cancer that overexpresses HER2. (Decision date - July 2012)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again